TG治疗 TGTX 深 沪
等待开盘 05-21 09:30:00 美东时间
39.76
+0.330
+0.84%
华盛通- 最 高40.64
- 今 开39.57
- 成交量 141.39万股
- 最 低 39.51
- 昨 收 39.43
- 总市值 608.66万
- 52周最高 44.65
- 市盈率 静 14.35
- 换手率 0.92%
- 52周最低 25.28
- 委 比 -10.81%
- 总股本 0.00亿
- 历史最高 56.74
- 量 比 0.89
- 振 幅 2.87%
- 历史最低 0.9563
- 每 手 1
- 风险率 3.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
财报速睇 | TG治疗 2026财年Q1营收2.05亿美元，同比增长69.6%；归母净利润0.20亿美元，同比增长290.9%
华盛资讯5月7日讯，TG治疗公布2026财年Q1业绩，公司Q1营收2.05亿美元，同比增长69.6%，归母净利润0.20亿美元，同比增长290.9%。
05-07 07:32
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
TG Therapeutics shares are trading higher after the company reported better-than-expected Q1 sales results and raised its FY2026 sales guidance above estimates.
TG Therapeutics shares are trading higher after the company reported better-tha...
05-07 01:29
财报速睇 | TG治疗 2026财年Q1营收2.05亿美元，同比增长69.6%；归母净利润0.20亿美元，同比增长290.9%
华盛资讯5月6日讯，TG治疗公布2026财年Q1业绩，公司Q1营收2.05亿美元，同比增长69.6%，归母净利润0.20亿美元，同比增长290.9%。
05-06 19:53
TG Therapeutics Raises FY2026 Sales Guidance from $875.000M-$900.000M to $925.000M vs $906.021M Est
TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $875.000 million-$900.000 million to $925.000 million vs $906.021 million estimate.
05-06 19:11
TG Therapeutics Completes Enrollment In A Phase 3 Trial Evaluating Subcutaneous BRIUMVI, Its Anti-CD20 Monoclonal Antibody, In People With Relapsing Forms Of Multiple Sclerosis
BRIUMVI is currently approved in the United States and several ex-US territories as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in adults with RMS. This is a Phase 3,
04-15 19:48
FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation
https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda
03-31 22:51
TG Therapeutics Enters Into 5-Yr, $750M Senior Secured Credit Facility With Funds Managed By Blue Owl Capital; Co. To Repay Outstanding $250M Senior Secured Credit Facility, Resulting In Net Raise Of $500M In Non-Dilutive Capital
TG Therapeutics, Inc. ("TG" or "the Company"), (NASDAQ:TGTX), today announced that it has entered into a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital ("Blue Owl"). As
03-19 19:37
TG Therapeutics Announces Presentation Dates For BRIUMVI Data On Relapsing Forms Of Multiple Sclerosis
TGTX announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2026
03-06 20:34
